Pediatrics Medicine Market - Forecast(2024 - 2030)
Pediatrics Medicine Market Overview
Pediatrics Medicine Market size was estimated at $101 billion in 2020, projected to grow at a CAGR of 5.2% during the forecast period 2021-2026. Pediatrics Medicine industry has witnessed huge demand owing to the rising pediatric diseases such as cystic fibrosis, asthma, and other infectious diseases. Montelukast sodium and clavulanate are the medicines used for asthma and variety of infectious diseases respectively. Pediatric medicine is a branch of medicine that is specifically designed for infants, children and adolescents.
The term Pediatrics means healer of children. The pediatric medicine is a combination of Pediatrics and emergency medicine. All pediatricians that deal with pediatric medicine are more concerned with congenital abnormalities, genetic variation and developmental problems. The pediatric medicine market grows significantly as children suffer from respiratory, gastrointestinal, allergic and other chronic diseases owing to their weaker immunity.
For instance, the Global Health Observatory (GHO) has released a fact sheet on
the leading causes of child mortality in 2018. According to 2017 figures,
diarrhea is the leading cause of the deaths among children, and neonatal deaths
was reported 47% of deaths among children under age 5, demanding for effective
treatment is boosting the market growth. Moreover, the pediatric medicine
market is growing owing to an increase in the prevalence of renal or pulmonary
dysfunctions and genetic disorders like cystic fibrosis.
Pediatrics Medicine Market Report Coverage
The report: “Pediatrics Medicine Market Forecast
(2021-2026)”, by Industry ARC, covers an in-depth analysis of the following
segments of the Pediatrics Medicine Market.
By Type of Medicine: Autoimmune Disorder Medicine, Respiratory Disorder Medicine,
Cardiovascular Medicine, Gastrointestinal Medicines
By Type of Disease: Infectious Disease, Respiratory diseases, CNS diseases,
Gastrointestinal diseases, Oncological diseases and others
By Route of Administration: Topical, Oral, Parenteral and Others
By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies
By Geography: North America (U.S., Canada, Mexico), Europe
(Germany, U.K., France, Italy, Spain, Russia and Rest of Europe), Asia Pacific
(China, Japan, India, South Korea, Australia & New Zealand, and Rest of
Asia Pacific), South America (Brazil, Argentina and Rest of South America), and
Rest of the World (Middle East and Africa)
Key Takeaways
- Geographically, North America Pediatrics Medicine Market held the largest revenue share of 37% in 2020 owing to the region demand.
- Significant R&D techniques adopted by the key players of the market is one of the major factors supporting global pediatric medicine market.
- Increase in FDA approvals for
pediatric medicine formulations are propelling the market for the Pediatrics
Medicine.
Pediatrics Medicine Market: Market Share (%) by Region, 2020
For more details on this report - Request for Sample
Pediatrics Medicine Market Segment Analysis – By Type of Medicine:
Based on Medicine Type, Pediatrics Medicine Market is segmented into Autoimmune Disorder Medicine, Respiratory Disorder Medicine, Cardiovascular Medicine, Gastrointestinal Medicines. Respiratory disorder segment is accounted for the largest revenue market share in 2020 owing to the lower immunity of children and growing pollution coupled with exposure of allergens that results in chronic respiratory disorders.
For
instance, Chronic obstructive pulmonary disease is a major cause of pediatric healthcare
burden. Montelukast is used for prophylaxis of asthma from age of 2 years and
older than that, where the predominant component is exercise induced
broncho-constriction. Autoimmune disorders segment is poised to grow with the
fastest CAGR of 5.8% in the forecast period 2021-2026. This is attributed to
the rising prevalence of genetic disorders, cancers and cystic Fibrosis that
provide incentives in order to assist and aid the development of medicines for
such rare autoimmune disorders.
Pediatrics Medicine Market Segment Analysis – By Route of Administration:
Based on route of administration, Pediatrics Medicine Market is segmented in to Topical, Oral, Parenteral and Others. Oral segment accounted for largest revenue market share in 2020. As Oral delivery of medicines is the most preferred route of administration for the pediatric patients owing to its non-invasive form and has less risk of pain. In addition, parents feel much comfortable to deliver medicine by this method, and leads to improved compliance for the medicine administrated via this route.
Topical segment is
anticipated to grow with the fastest CAGR of 5.9% in the forecast period
2021-2026. This is owing to the low risk of adverse reactions and drug
interactions coupled with ease of administration to a child. Moreover, very
less amount of drug is used, low cost and high concentration of antibiotics
while applied on affected area are some of the factors contributing to the
growth of this segment in the Pediatrics medicine market.
Pediatrics Medicine Market Segment Analysis – By Geography:
Based on Geography, North America Pediatrics Medicine Market accounted for the 37% revenue share in 2020. This is majorly attributed to the rising number of pediatric cases that are suffering from various respiratory disorders, autoimmune disorders, muscular atrophy, cerebral palsy coupled with adoption of advanced technologies in the U.S. for instance, American Academy of allergy, Asthma & Immunology statistics has estimated that in 2018, more than 40% children in the U.S have allergies thereby rising demand for pediatric medicine is boosting the market in this region.
Cystic fibrosis is a most common genetic disorder among white people in the U.S. It occurs in 1 in 2,500 to 3,500 white new born. Whereas, Cystic fibrosis is less common in other groups, it affects about 1 in 17,000 African Americans and 1 in 31,000 Asian Americans. Moreover, the launch of new products by the market’s major players in this region, government initiatives that creates awareness in people for pediatric medicines like Montelukast sodium, clavulanic acid and others and early approvals by the USFDA aid to the growth of the market in this region. Asia-Pacific market is poised to grow with the fastest CAGR in the forecast period 2021-2026 owing its increase in population, increasing health care expenditure coupled with government initiatives and other healthcare policies in this region is contributing to the growth of the market in this region.
Pediatrics Medicine Market Segment Analysis-Drivers
Increasing development of Pediatric Medicine Formulations:
Over the past two decades, regulators have made considerable
efforts to encourage pharmaceutical companies in order to develop pediatric
medicines, especially orphan drugs for the rare and ultra rare diseases and
drugs for cystic fibrosis. Over the last few years, new regulations and
legislation have resulted in a substantial increase in the number of new route
of administration options for the patients in this category. Designing,
recruiting and running various pediatric clinical trials, as well as
determining acceptable end points are still difficult tasks, but many major
clinical research organizations now provide specialized services in this field.
Moreover, the increase in FDA approvals of such medicines is further
contributing to the growth of the market. For instance, in May 2019, Jacobus
Pharmaceutical company has received an U.S. FDA approval under Priority Review
and Fast Track designations for RUZURGI tablets (amifampridine). It also
received orphan drug designation for treating Lambert Eaton myathenic syndrome
(LEMS) in pediatric population.
Pediatrics Medicine Market Segment Analysis-Challenges
Lack of Understanding Amongst Physicians Regarding Effectiveness of Medicines:
Despite of the major difficulties and
cost associated with developing age appropriate formulations, medicines for
treating pediatric conditions are becoming more difficult. As they are specific
formulations formulated for certain age group, sometimes they lack in providing
label instructions for the pediatric patients. Moreover, physicians rarely rely
on their clinical judgement to study it and know how to administer a medicine
and what was it intended for. This approach increase the risk, as too much
medicine turns to be toxic, and too little is said to be ineffective for the
treatment.
Pediatrics Medicine Market Segment Landscape:
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Pediatrics Medicine Market. Pediatrics
Medicine Market top 10 companies are Cipla, Inc., Lupin, Pfizer Inc., F.
Hoffman-La Roche Ltd, Sanofi S.A., Abbott Laboratories, Eli Lilly &
Company, Merck Co.Ltd., Heron Therapeutics Inc., Novartis A.G.
Acquisitions/Product Launches
In April 2019, GSK has received approval from U.S. Food and Drug administration for its intravenous Benlysta, the first ever medicine in the US to be approved for children suffering from systemic lupus erythematous (SLE).
Related Reports
Pediatric
Market Forecast (2021-2026)
Report Code: HCR 0028
Pediatric
Supplements Market Forecast (2021-2026)
Report Code: FBR 0086
For more Lifesciences and Healthcare Market reports, please click here
LIST OF TABLES
1.Global GLOBAL PEDIATRICS MEDICINE MARKET, BY TYPE Market 2023-2030 ($M)1.1 SHORT TERM ILLNESS Market 2023-2030 ($M) - Global Industry Research
1.1.1 Cystic Fibrosis Market 2023-2030 ($M)
1.1.2 Ear Infection Market 2023-2030 ($M)
1.1.3 Upper Respiratory Infections Market 2023-2030 ($M)
1.2 CHRONIC ILLNESS Market 2023-2030 ($M) - Global Industry Research
1.2.1 Diabetes Market 2023-2030 ($M)
2.Global GLOBAL PEDIATRICS MEDICINE MARKET, BY TYPE Market 2023-2030 (Volume/Units)
2.1 SHORT TERM ILLNESS Market 2023-2030 (Volume/Units) - Global Industry Research
2.1.1 Cystic Fibrosis Market 2023-2030 (Volume/Units)
2.1.2 Ear Infection Market 2023-2030 (Volume/Units)
2.1.3 Upper Respiratory Infections Market 2023-2030 (Volume/Units)
2.2 CHRONIC ILLNESS Market 2023-2030 (Volume/Units) - Global Industry Research
2.2.1 Diabetes Market 2023-2030 (Volume/Units)
3.North America GLOBAL PEDIATRICS MEDICINE MARKET, BY TYPE Market 2023-2030 ($M)
3.1 SHORT TERM ILLNESS Market 2023-2030 ($M) - Regional Industry Research
3.1.1 Cystic Fibrosis Market 2023-2030 ($M)
3.1.2 Ear Infection Market 2023-2030 ($M)
3.1.3 Upper Respiratory Infections Market 2023-2030 ($M)
3.2 CHRONIC ILLNESS Market 2023-2030 ($M) - Regional Industry Research
3.2.1 Diabetes Market 2023-2030 ($M)
4.South America GLOBAL PEDIATRICS MEDICINE MARKET, BY TYPE Market 2023-2030 ($M)
4.1 SHORT TERM ILLNESS Market 2023-2030 ($M) - Regional Industry Research
4.1.1 Cystic Fibrosis Market 2023-2030 ($M)
4.1.2 Ear Infection Market 2023-2030 ($M)
4.1.3 Upper Respiratory Infections Market 2023-2030 ($M)
4.2 CHRONIC ILLNESS Market 2023-2030 ($M) - Regional Industry Research
4.2.1 Diabetes Market 2023-2030 ($M)
5.Europe GLOBAL PEDIATRICS MEDICINE MARKET, BY TYPE Market 2023-2030 ($M)
5.1 SHORT TERM ILLNESS Market 2023-2030 ($M) - Regional Industry Research
5.1.1 Cystic Fibrosis Market 2023-2030 ($M)
5.1.2 Ear Infection Market 2023-2030 ($M)
5.1.3 Upper Respiratory Infections Market 2023-2030 ($M)
5.2 CHRONIC ILLNESS Market 2023-2030 ($M) - Regional Industry Research
5.2.1 Diabetes Market 2023-2030 ($M)
6.APAC GLOBAL PEDIATRICS MEDICINE MARKET, BY TYPE Market 2023-2030 ($M)
6.1 SHORT TERM ILLNESS Market 2023-2030 ($M) - Regional Industry Research
6.1.1 Cystic Fibrosis Market 2023-2030 ($M)
6.1.2 Ear Infection Market 2023-2030 ($M)
6.1.3 Upper Respiratory Infections Market 2023-2030 ($M)
6.2 CHRONIC ILLNESS Market 2023-2030 ($M) - Regional Industry Research
6.2.1 Diabetes Market 2023-2030 ($M)
7.MENA GLOBAL PEDIATRICS MEDICINE MARKET, BY TYPE Market 2023-2030 ($M)
7.1 SHORT TERM ILLNESS Market 2023-2030 ($M) - Regional Industry Research
7.1.1 Cystic Fibrosis Market 2023-2030 ($M)
7.1.2 Ear Infection Market 2023-2030 ($M)
7.1.3 Upper Respiratory Infections Market 2023-2030 ($M)
7.2 CHRONIC ILLNESS Market 2023-2030 ($M) - Regional Industry Research
7.2.1 Diabetes Market 2023-2030 ($M)
LIST OF FIGURES
1.US Pediatrics Medicine Market Revenue, 2023-2030 ($M)2.Canada Pediatrics Medicine Market Revenue, 2023-2030 ($M)
3.Mexico Pediatrics Medicine Market Revenue, 2023-2030 ($M)
4.Brazil Pediatrics Medicine Market Revenue, 2023-2030 ($M)
5.Argentina Pediatrics Medicine Market Revenue, 2023-2030 ($M)
6.Peru Pediatrics Medicine Market Revenue, 2023-2030 ($M)
7.Colombia Pediatrics Medicine Market Revenue, 2023-2030 ($M)
8.Chile Pediatrics Medicine Market Revenue, 2023-2030 ($M)
9.Rest of South America Pediatrics Medicine Market Revenue, 2023-2030 ($M)
10.UK Pediatrics Medicine Market Revenue, 2023-2030 ($M)
11.Germany Pediatrics Medicine Market Revenue, 2023-2030 ($M)
12.France Pediatrics Medicine Market Revenue, 2023-2030 ($M)
13.Italy Pediatrics Medicine Market Revenue, 2023-2030 ($M)
14.Spain Pediatrics Medicine Market Revenue, 2023-2030 ($M)
15.Rest of Europe Pediatrics Medicine Market Revenue, 2023-2030 ($M)
16.China Pediatrics Medicine Market Revenue, 2023-2030 ($M)
17.India Pediatrics Medicine Market Revenue, 2023-2030 ($M)
18.Japan Pediatrics Medicine Market Revenue, 2023-2030 ($M)
19.South Korea Pediatrics Medicine Market Revenue, 2023-2030 ($M)
20.South Africa Pediatrics Medicine Market Revenue, 2023-2030 ($M)
21.North America Pediatrics Medicine By Application
22.South America Pediatrics Medicine By Application
23.Europe Pediatrics Medicine By Application
24.APAC Pediatrics Medicine By Application
25.MENA Pediatrics Medicine By Application
26.LUPIN, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.GLAXOSMITHKLINE PLC, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.PFIZER INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.SANOFI S.A., Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.F.HOFFMAN-LA ROCHE LTD., Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.ABBOTT LABORATORIES, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.HERON THERAPEUTICS, INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.ELI LILLY AND COMPANY, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.NOVARTIS A.G, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.CIPLA INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)